If an underlying condition is responsible (liver disease, kidney disease, myeloproliferative disorder, or cancer), treating the underlying condition is the priority
[DOI] [PMC free article] [PubMed] [Google Scholar] Xu B, Wratten N, Charych EI, Buyske S, Firestein BL, Brzustowicz LM
However, our results show that glucagon increased lipolysis in vivo at 6 h
& Carlsten, H
Healthcare providers should counsel patients about this theoretical risk before initiating treatment, particularly those with personal or family histories of thyroid malignancy or multiple endocrine neoplasia syndromes
As of May 2026, retatrutide doesnt have a UK marketing authorisation, which means no UK pharmacy or licensed clinic can legally dispense it